市場調査レポート

世界の2型糖尿病の治療薬市場の分析

Analysis of the Global Type 2 Diabetes Therapeutics Market

発行 Frost & Sullivan 商品コード 283274
出版日 ページ情報 英文 326 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
世界の2型糖尿病の治療薬市場の分析 Analysis of the Global Type 2 Diabetes Therapeutics Market
出版日: 2013年09月23日 ページ情報: 英文 326 Pages
概要

2型糖尿病は現在、世界で最も深刻な疾患の一つとなっており、その患者数や市場規模の大きさから、数多くのパイプライン製品が現在開発され、血糖値の制御・安全性の改善・利便性の向上といったアンメットニーズに応えようとしています。

当レポートでは、全世界の2型糖尿病の治療法の開発・市場動向について分析し、疾患の概要や市場の促進・抑制要因、市場全体の動向見通し(過去4年間の実績値と今後5年間の予測値)、部門別(インスリン/非インスリン製品、上市済み/開発中)の詳細動向、各国市場の概況(収益予測、部門別詳細、価格・医療費還付動向、規制体制など)、主要企業の概況などを調査・推計して、その結果を概略以下の構成でお届けします。

第1章 エグゼクティブ・サマリー

第2章 市場概要

  • 市場の背景
  • 市場の内訳と関連議論
  • 世界市場の見通し
  • 将来の医療市場動向の定義

第3章 競争戦略

  • 新たな市場機会
  • 企業合併・買収(M&A)およびパートナーシップ契約

第4章 市場促進・抑制要因:市場全体の場合

第5章 市場の予測と傾向:市場全体の場合

  • 市場エンジニアリング計測
  • 予測の前提条件と定義
  • 市場収益の予測
  • 地域別の収益予測

第6章 競争環境

  • 上市済み/パイプライン製品の件数
  • 上市済み製品の一覧:インスリン部門(即効性/中間型(プレミックス)/基礎インスリン)
  • パイプライン製品の一覧:インスリン部門(治験の初期/中期/後期段階)
  • 競争環境:非インスリン部門(上市済み/パイプライン製品(初期・後期段階))
  • 上市済み製品の一覧:非インスリン部門(主力/副次的製品)
  • 上市済み製品のプロファイル:非インスリン部門(DPP-4/GLP-1/SGLT2クラス)
  • パイプライン製品:非インスリン部門(治験の初期/中期/後期段階)
  • 市場シェアの進化・分析
  • 主な企業
  • 製品発売の年表
  • 特許失効:インスリン/非インスリン部門
  • 主要製品の独占販売期間:インスリン/非インスリン部門
  • 心血管疾患の治験結果の年表
  • 治験の最終段階にある有望な医薬品:プロファイルの比較分析
  • 製品の効能の比較分析

第7章 インスリン部門の詳細分析

  • 主な分析結果
  • 市場エンジニアリング計測
  • 市場予測および関連議論

第8章 非インスリン部門の詳細分析

  • 主な分析結果
  • 市場エンジニアリング計測
  • 市場予測および関連議論

第9章 米国市場の詳細分析

第10章 英国市場の詳細分析

第11章 ドイツ市場の詳細分析

第12章 フランス市場の詳細分析

第13章 イタリア市場の詳細分析

第14章 スペイン市場の詳細分析

第15章 ベネルクス諸国市場の詳細分析

第16章 北欧諸国市場の詳細分析

第17章 中国市場の詳細分析

第18章 韓国市場の詳細分析

第19章 マレーシア市場の詳細分析

第20章 インドネシア市場の詳細分析

第21章 ベトナム市場の詳細分析

第22章 インド市場の詳細分析

第23章 顧客・エンドユーザーの分析

第24章 注目すべき主要企業

  • 注目すべき企業
  • DiaMedica, Inc.
  • Eli Lilly
  • Elcelyx Therapeutics, Inc.
  • Novo Nordisk

第25章 結論

第26章 付録

図表一覧

目次
Product Code: NC67-01-00-00-00

Type 2 diabetes is one of the most significant global health concerns of modern times. The size of the diabetes therapeutics market has stimulated a vast and growing pipeline of potential new therapies aimed at the unmet needs of tighter glucose control, improved safety profiles, and greater convenience to patients. This research service evaluates the global market for the pharmaceutical management of type 2 diabetes from 2009 to 2017, with 2012 as the base year. Segmentation by drug type (insulin and non-insulin therapeutics) and regional breakdown are provided. Included are products available in the market, products in development, and patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed.

Table of Contents

1. Executive Summary

  • Key Findings
  • Scope and Segmentation
  • Key Questions This Study Will Answer
  • Market Engineering Measurements
  • CEO's Perspective
  • Key Companies to Watch
  • Executive Summary-3 Big Predictions

2. Market Overview

  • Market Background
  • Market Segmentation
  • Market Segmentation Discussion
  • Global Market Perspective
  • Defining Healthcare Trends in the Future

3. Competitive Playbook

  • New Market Opportunities
  • Merger, Acquisition, and Partnership Assessment

4. Driver, Restraints, and Trends-Total Type 2 Diabetes Therapeutics Market

  • Market Drivers
  • Market Restraints

5. Forecasts and Trends-Total Type 2 Diabetes Therapeutics Market

  • Market Engineering Measurements
  • Forecast Assumptions and Definitions
  • Revenue Forecast
  • Revenue Forecast Discussion
  • Percent Revenue Forecast by Region
  • Revenue Forecast by Region

6. Competitive Environment

  • Competitive Landscape-Insulin Segment, Count of Marketed and Pipeline Products
  • Marketed Product Synopsis-Insulin Segment
  • Marketed Product Profiles-Insulin Segment Rapid-acting Insulin
  • Marketed Product Profiles-Insulin Segment Intermediate-acting/Premix Insulin
  • Marketed Product Profiles-Insulin Segment Basal Insulin
  • Pipeline Analysis-Insulin Segment Products in Late-stage Clinical Development
  • Pipeline Analysis-Insulin Segment Products in Mid-stage Clinical Development
  • Pipeline Analysis-Insulin Segment Products in Early-stage Clinical Development
  • Competitive Landscape-Non-insulin Segment Count of Marketed and Pipeline Products
  • Competitive Landscape-Non-insulin Segment Late-stage and Marketed Products
  • Competitive Landscape-Non-insulin Segment Early-stage Pipeline Products
  • Marketed Product Synopsis-Non-insulin Segment First Line Standard of Care Products
  • Marketed Product Synopsis-Non-insulin Segment Add-on Products
  • Marketed Product Profiles-Non-insulin Segment DPP-4 Class
  • Marketed Product Profiles-Non-insulin Segment GLP-1 Class
  • Marketed Product Profiles-Non-insulin Segment SGLT2 Class
  • Pipeline Analysis-Non-insulin Segment Products in Late-stage Clinical Development
  • Pipeline Analysis-Non-insulin Segment Products in Mid-stage Clinical Development
  • Pipeline Analysis-Non-insulin Segment Products in Early-stage Clinical Development
  • Market Share Evolution
  • Market Share Analysis
  • Top Competitors
  • Timeline of Product Launches
  • Patent Expirations-Insulin Segment
  • Patent Expirations-Non-insulin Segment
  • Exclusivity Periods of Key Products-Modern Insulins
  • Exclusivity Periods of Key Products-Non-insulin Segment
  • Cardiovascular Outcomes Trials Timeline
  • Comparative Product Profiles of Promising Late-stage Candidates
  • Comparative Efficacy Analysis
  • Comparative Efficacy Analysis Discussion

7. Insulin Segment Breakdown

  • Insulin Segment Key Findings
  • Market Engineering Measurements
  • Revenue Forecast
  • Revenue Forecast Discussion

8. Non-insulin Segment Breakdown

  • Non-insulin Segment Key Findings
  • Market Engineering Measurements
  • Revenue Forecast
  • Revenue Forecast Discussion

9. United States (US) Breakdown

  • Insulin Segment Revenue Forecast
  • Insulin Segment Revenue Forecast by Class
  • Insulin Segment Revenue Forecast Discussion
  • Insulin Segment Type 2 Diabetes Prevalence and Treated Patient Forecast
  • Insulin Segment Type 2 Diabetes Prevalence and Treated Patient Forecast Discussion
  • Non-insulin Segment Revenue Forecast
  • Non-insulin Segment Revenue Forecast by Class
  • Non-insulin Segment Revenue Forecast Discussion
  • Non-insulin Segment Type 2 Diabetes Prevalence and Treated Patient Forecast
  • Non-insulin Segment Type 2 Diabetes Prevalence and Treated Patient Forecast Discussion
  • Pricing Analysis
  • Market Analysis
  • PESTLE Analysis

10. United Kingdom (UK) Breakdown

  • The UK Diabetes Outlook
  • Insulin Segment Revenue Forecast
  • Insulin Segment Revenue Forecast Discussion
  • Non-insulin Segment Revenue Forecast
  • Non-insulin Segment Revenue Forecast Discussion
  • Regulatory Policy Framework
  • Pricing and Reimbursement
  • Type 2 Diabetes Prevalence Forecast
  • Type 2 Diabetes Prevalence Forecast Discussion
  • Market Analysis

11. Germany Breakdown

  • Germany Diabetes Outlook
  • Insulin Segment Revenue Forecast
  • Insulin Segment Revenue Forecast Discussion
  • Non-insulin Segment Revenue Forecast
  • Non-insulin Segment Revenue Forecast Discussion
  • Regulatory Policy Framework
  • Pricing and Reimbursement
  • Type 2 Diabetes Prevalence Forecast
  • Type 2 Diabetes Prevalence Forecast Discussion
  • Market Analysis

12. France Breakdown

  • France Diabetes Outlook
  • Insulin Segment Revenue Forecast
  • Insulin Segment Revenue Forecast Discussion
  • Non-insulin Segment Revenue Forecast
  • Non-insulin Segment Revenue Forecast Discussion
  • Regulatory Policy Framework
  • Pricing and Reimbursement
  • Type 2 Diabetes Prevalence Forecast
  • Type 2 Diabetes Prevalence Forecast Discussion
  • Market Analysis

13. Italy Breakdown

  • Italy Diabetes Outlook
  • Insulin Segment Revenue Forecast
  • Insulin Segment Revenue Forecast Discussion
  • Non-insulin Segment Revenue Forecast
  • Non-insulin Segment Revenue Forecast Discussion
  • Regulatory Policy Framework
  • Pricing and Reimbursement
  • Type 2 Diabetes Prevalence Forecast
  • Type 2 Diabetes Prevalence Forecast Discussion
  • Market Analysis

14. Spain Breakdown

  • Spain Diabetes Outlook
  • Insulin Segment Revenue Forecast
  • Insulin Segment Revenue Forecast Discussion
  • Non-insulin Segment Revenue Forecast
  • Non-insulin Segment Revenue Forecast Discussion
  • Regulatory Policy Framework
  • Pricing and Reimbursement
  • Type 2 Diabetes Prevalence Forecast
  • Type 2 Diabetes Prevalence Forecast Discussion
  • Market Analysis

15. Benelux Breakdown

  • Benelux Diabetes Outlook
  • Insulin Segment Revenue Forecast
  • Insulin Segment Revenue Forecast Discussion
  • Non-insulin Segment Revenue Forecast
  • Non-insulin Segment Revenue Forecast Discussion
  • Regulatory Policy Framework
  • Pricing and Reimbursement
  • Type 2 Diabetes Prevalence Forecast
  • Type 2 Diabetes Prevalence Forecast Discussion
  • Market Analysis

16. Scandinavia Breakdown

  • Scandinavia Diabetes Outlook
  • Insulin Segment Revenue Forecast
  • Insulin Segment Revenue Forecast Discussion
  • Non-insulin Segment Revenue Forecast
  • Non-insulin Segment Revenue Forecast Discussion
  • Regulatory Policy Framework
  • Pricing and Reimbursement
  • Type 2 Diabetes Prevalence Forecast
  • Type 2 Diabetes Prevalence Forecast Discussion
  • Market Analysis

17. China Breakdown

  • Market Overview
  • Insulin Segment Revenue Forecast
  • Insulin Segment Revenue Forecast Discussion
  • Non-insulin Segment Revenue Forecast
  • Non-insulin Segment Revenue Forecast Discussion
  • Pricing Analysis
  • Type 2 Diabetes Prevalence and Treated Patient Forecast
  • Type 2 Diabetes Prevalence and Treated Patient Forecast Discussion
  • Market Analysis

18. South Korea Breakdown

  • South Korea Diabetes Outlook
  • Insulin Segment Revenue Forecast
  • Insulin Segment Revenue Forecast Discussion
  • Non-insulin Segment Revenue Forecast
  • Non-insulin Segment Revenue Forecast Discussion
  • Pricing Analysis
  • Type 2 Diabetes Prevalence and Treated Patient Forecast
  • Type 2 Diabetes Prevalence and Treated Patient Forecast Discussion
  • Market Analysis

19. Malaysia Breakdown

  • Malaysia Diabetes Outlook
  • Insulin Segment Revenue Forecast
  • Insulin Segment Revenue Forecast Discussion
  • Non-insulin Segment Revenue Forecast
  • Non-insulin Segment Revenue Forecast Discussion
  • Pricing Analysis
  • Type 2 Diabetes Prevalence and Treated Patient Forecast
  • Type 2 Diabetes Prevalence and Treated Patient Forecast Discussion
  • Market Analysis

20. Indonesia Breakdown

  • Indonesia Diabetes Outlook
  • Insulin Segment Revenue Forecast
  • Insulin Segment Revenue Forecast Discussion
  • Non-insulin Segment Revenue Forecast
  • Non-insulin Segment Revenue Forecast Discussion
  • Pricing Analysis
  • Type 2 Diabetes Prevalence and Treated Patient Forecast
  • Type 2 Diabetes Prevalence and Treated Patient Forecast Discussion
  • Market Analysis

21. Vietnam Breakdown

  • Vietnam Diabetes Outlook
  • Insulin Segment Revenue Forecast
  • Insulin Segment Revenue Forecast Discussion
  • Non-insulin Segment Revenue Forecast
  • Non-insulin Segment Revenue Forecast Discussion
  • Pricing Analysis
  • Type 2 Diabetes Prevalence and Treated Patient Forecast
  • Type 2 Diabetes Prevalence and Treated Patient Forecast Discussion
  • Market Analysis

22. India Breakdown

  • Insulin Segment Revenue Forecast
  • Insulin Segment Revenue Forecast Discussion
  • Non-insulin Segment Revenue Forecast
  • Non-insulin Segment Revenue Forecast Discussion
  • Pricing Analysis
  • Type 2 Diabetes Prevalence and Treated Patient Forecast
  • Type 2 Diabetes Prevalence and Treated Patient Forecast Discussion
  • Market Analysis

23. Customer and End-user Analysis

  • KOL Commentary

24. Key Companies to Watch

  • Companies to Watch
  • DiaMedica, Inc.
  • Eli Lilly
  • Elcelyx Therapeutics, Inc.
  • Novo Nordisk

25. The Last Word

  • The Last Word-3 Big Predictions
  • The Last Word-Discussion
  • Legal Disclaimer

26. Appendix

  • Drivers Explained
  • Restraints Explained
  • Decision Support Database
  • Additional Sources of Information on Diabetes
  • Market Engineering Methodology
  • Learn More-Next Steps

List of Exhibits

  • Analysis of the Global Type 2 Diabetes Therapeutics Market
  • Market Opportunities for Differentiated Therapeutics
  • Type 2 diabetes is one of the most significant global health concerns of modern times. The size of the diabetes therapeutics market has stimulated a vast and growing pipeline of potential new therapies aimed at the unmet needs of tighter glucose control, improved safety profiles, and greater convenience to patients. This research service evaluates the global market for the pharmaceutical management of type 2 diabetes from 2009 to 2017, with 2012 as the base year. Segmentation by drug type (insulin and non-insulin therapeutics) and regional breakdown are provided. Included are products available in the market, products in development, and patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed.
  • Total Type 2 Diabetes Therapeutics Market: Market Engineering Measurements, Global, 2012
  • Total Type 2 Diabetes Therapeutics Market: Diagnostic Criteria, Global, 2012
  • Total Type 2 Diabetes Therapeutics Market: Market Segmentation, Global, 2012
  • Total Type 2 Diabetes Therapeutics Market: Growth Rate Breakdown by Geographic Region, Global, 2012
  • Total Type 2 Diabetes Therapeutics Market: Market Outlook, Global, 2012 and 2022
  • Total Type 2 Diabetes Therapeutics Market: Game-changing Strategies, Global, 2012
  • Total Type 2 Diabetes Therapeutics Market: Market Outlook, Global, 2007-2013
  • Total Type 2 Diabetes Therapeutics Market: Key Market Drivers, Global, 2013-2017
  • Total Type 2 Diabetes Therapeutics Market: Key Market Restraints, Global, 2013-2017
  • Total Type 2 Diabetes Therapeutics Market: Market Engineering Measurements, Global, 2012
  • Total Type 2 Diabetes Therapeutics Market: Revenue Forecast, Global, 2009-2017
  • Total Type 2 Diabetes Therapeutics Market: Major New Product Launches, Global, 2013-2017
  • Total Type 2 Diabetes Therapeutics Market: Percent Revenue Forecast by Region, Global, 2009-2017
  • Total Type 2 Diabetes Therapeutics Market: Revenue Forecast by Region, Global, 2009-2017
  • Total Type 2 Diabetes Therapeutics Market: Competitive Landscape-Insulin Segment, Count of Marketed and Pipeline Products by Type and Phase, Global, 2012
  • Total Type 2 Diabetes Therapeutics Market: Competitive Landscape-Insulin Segment, Marketed and Pipeline Products by Type, Global, 2012
  • Total Type 2 Diabetes Therapeutics Market: Insulin Segment, Marketed Product Synopsis, Global, 2012
  • Total Type 2 Diabetes Therapeutics Market: Insulin Segment Marketed Product Profiles, Rapid-acting Insulin, Global, 2012
  • Total Type 2 Diabetes Therapeutics Market: Insulin Segment Marketed Product Profiles, Intermediate-acting/Premix Insulin, Global, 2012
  • Total Type 2 Diabetes Therapeutics Market: Insulin Segment Marketed Product Profiles, Basal Insulin, Global, 2012
  • Total Type 2 Diabetes Therapeutics Market: Insulin Segment, Late-stage Product Synopsis, Global, 2012
  • Total Type 2 Diabetes Therapeutics Market: Insulin Segment, Mid-stage Product Synopsis, Global, 2012
  • Total Type 2 Diabetes Therapeutics Market: Insulin Segment-Early-stage Product Synopsis, Global, 2012
  • Total Type 2 Diabetes Therapeutics Market: Competitive Landscape-Non-insulin Segment, Count of Marketed and Pipeline Products by Type and Phase, Global, 2012
  • Total Type 2 Diabetes Therapeutics Market: Competitive Landscape-Non-Insulin Segment, Late-stage and Marketed Products by Drug Class, Global, 2012
  • Total Type 2 Diabetes Therapeutics Market: Competitive Landscape-Non-Insulin Segment, Early-stage Pipeline Products by Drug Class, Global, 2012
  • Total Type 2 Diabetes Therapeutics Market: Non-insulin Segment, Standard of Care Marketed Product Synopsis, Global, 2012
  • Total Type 2 Diabetes Therapeutics Market: Non-insulin Segment, Add-on Marketed Product Synopsis, Global, 2012
  • Total Type 2 Diabetes Therapeutics Market: Non-insulin Segment Marketed Product Profiles, DPP-4s, Global, 2012
  • Total Type 2 Diabetes Therapeutics Market: Non-insulin Segment Marketed Product Profiles, GLP-1s, Global, 2012
  • Total Type 2 Diabetes Therapeutics Market: Non-insulin Segment Marketed Product Profiles, SGLT2s, Global, 2012
  • Total Type 2 Diabetes Therapeutics Market: Non-Insulin Segment, Late-stage Product Synopsis, Global, 2012
  • Total Type 2 Diabetes Therapeutics Market: Non-Insulin Segment, Mid-stage Product Synopsis, Global, 2012
  • Total Type 2 Diabetes Therapeutics Market: Non-Insulin Segment, Early-stage Product Synopsis, Global, 2012
  • Total Type 2 Diabetes Therapeutics Market: Absolute Market Share Trend by Revenue, Global, 2009 and 2012
  • Total Type 2 Diabetes Therapeutics Market: Company Market Share Analysis of Top 5 Participants, Global, 2012
  • Total Type 2 Diabetes Therapeutics Market: SWOT Analysis, Global, 2012
  • Total Type 2 Diabetes Therapeutics Market: Timeline of Product Launches, Global, 2010-2018
  • Total Type 2 Diabetes Therapeutics Market: Patent Expirations, Insulin Segment, Global, 2000-2030
  • Total Type 2 Diabetes Therapeutics Market: Patent Expirations-Non-insulin Segment, Global, 2000-2030
  • Total Type 2 Diabetes Therapeutics Market: Exclusivity Periods of Major Products-Modern Insulins, Global, 2000-2030
  • Total Type 2 Diabetes Therapeutics Market: Exclusivity Periods of Major Products-Non-insulin Segment, Global, 2000-2030
  • Total Type 2 Diabetes Therapeutics Market: Cardiovascular Outcomes Trials Timeline, Global, 2012
  • Total Type 2 Diabetes Therapeutics Market: Comparative Product Profiles of Promising Late-stage Candidates, Global, 2012
  • Total Type 2 Diabetes Therapeutics Market: Comparative HbA1c Lowering of Selected Marketed Drugs, Global, 2012
  • Total Type 2 Diabetes Market: Comparative HbA1c Lowering of Selected Marketed Drugs, Global, 2012
  • Insulin Segment: Percent Sales Breakdown, Global, 2012
  • Insulin Segment: Market Engineering Measurements, Global, 2012
  • Insulin Segment: Revenue Forecast, Global, 2009-2017
  • Non-insulin Segment: Percent Sales Breakdown, Global, 2012
  • Non-insulin Segment: Market Engineering Measurements, Global, 2012
  • Non-insulin Segment: Revenue Forecast, Global, 2009-2017
  • Insulin Segment: Revenue Forecast, US, 2009-2017
  • Insulin Segment: Revenue Forecast by Class, US, 2009-2017
  • Insulin Segment: Type 2 Diabetes Prevalence and Treated Patient Forecast, US, 2009-2017
  • Non-insulin Segment: Revenue Forecast, US, 2009-2017
  • Non-insulin Segment: Revenue Forecast by Class, US, 2009-2017
  • Non-insulin Segment: Evolution of Market Share by Drug Class, US, 2012 and 2017
  • Non-insulin Segment: Type 2 Diabetes Prevalence and Treated Patient Forecast, US, 2009-2017
  • Type 2 Diabetes Therapeutics Market: Pricing Analysis, US, 2012
  • Type 2 Diabetes Therapeutics Market: PESTLE Analysis, US, 2012
  • Type 2 Diabetes Therapeutics Market: Diabetes Outlook, UK, 2012 and 2030
  • Insulin Segment: Revenue Forecast, UK, 2009-2017
  • Non-insulin Segment: Revenue Forecast, UK, 2009-2017
  • Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework, UK, 2012
  • Type 2 Diabetes Therapeutics Market: Prevalence Forecast, UK, 2009-2017
  • Type 2 Diabetes Therapeutics Market: Diabetes Outlook, Germany, 2012 and 2030
  • Insulin Segment: Revenue Forecast, Germany, 2009-2017
  • Non-insulin Segment: Revenue Forecast, Germany, 2009-2017
  • Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework, Germany, 2012
  • Type 2 Diabetes Therapeutics Market: Reimbursement Status, Germany, 2012
  • Type 2 Diabetes Therapeutics Market: Prevalence Forecast, Germany, 2009-2017
  • Type 2 Diabetes Therapeutics Market: Diabetes Outlook, France, 2012 and 2030
  • Insulin Segment: Revenue Forecast, France, 2009-2017
  • Non-insulin Segment: Revenue Forecast, France, 2009-2017
  • Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework, France, 2012
  • Type 2 Diabetes Therapeutics Market: Prevalence Forecast, France, 2009-2017
  • Type 2 Diabetes Therapeutics Market: Diabetes Outlook, Italy, 2012 and 2030
  • Insulin Segment: Revenue Forecast, Italy, 2009-2017
  • Non-insulin Segment: Revenue Forecast, Italy, 2009-2017
  • Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework, Italy, 2012
  • Type 2 Diabetes Therapeutics Market: Prevalence Forecast, Italy, 2009-2017
  • Type 2 Diabetes Therapeutics Market: Diabetes Outlook, Spain, 2012 and 2030
  • Insulin Segment: Revenue Forecast, Spain, 2009-2017
  • Non-insulin Segment: Revenue Forecast, Spain, 2009-2017
  • Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework, Spain, 2012
  • Type 2 Diabetes Therapeutics Market: Prevalence Forecast, Spain, 2009-2017
  • Type 2 Diabetes Therapeutics Market: Diabetes Outlook, Benelux, 2012 and 2030
  • Insulin Segment: Revenue Forecast, Benelux, 2009-2017
  • Non-insulin Segment: Revenue Forecast, Benelux, 2009-2017
  • Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework, Belgium, 2012
  • Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework, the Netherlands, 2012
  • Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework, Luxembourg, 2012
  • Type 2 Diabetes Therapeutics Market: Prevalence Forecast, Benelux, 2009-2017
  • Type 2 Diabetes Therapeutics Market: Diabetes Outlook, Scandinavia, 2012 and 2030
  • Insulin Segment: Revenue Forecast, Scandinavia, 2009-2017
  • Non-insulin Segment: Revenue Forecast, Scandinavia, 2009-2017
  • Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework, Norway, 2012
  • Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework, Sweden, 2012
  • Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework, Denmark, 2012
  • Type 2 Diabetes Therapeutics Market: Regulatory Policy Framework, Finland, 2012
  • Type 2 Diabetes Therapeutics Market: Prevalence Forecast, Scandinavia, 2009-2017
  • Insulin Segment: Revenue Forecast, China, 2009-2017
  • Non-insulin Segment: Revenue Forecast, China, 2009-2017
  • Type 2 Diabetes Therapeutics Market: Pricing Analysis, China, 2012
  • Type 2 Diabetes Therapeutics Market: Prevalence and Treated Patient Forecast, China, 2009-2017
  • Type 2 Diabetes Therapeutics Market: Range of Reported Disease Prevalence Estimates, China, 2012
  • Type 2 Diabetes Therapeutics Market: Diabetes Outlook, South Korea, 2012 and 2030
  • Insulin Segment: Revenue Forecast, South Korea, 2009-2017
  • Non-insulin Segment: Revenue Forecast, South Korea, 2009-2017
  • Type 2 Diabetes Therapeutics Market: Pricing Analysis, South Korea, 2012
  • Type 2 Diabetes Therapeutics Market: Prevalence and Treated Patient Forecast, South Korea, 2009-2017
  • Type 2 Diabetes Therapeutics Market: Diabetes Outlook, Malaysia, 2012 and 2030
  • Insulin Segment: Revenue Forecast, Malaysia, 2009-2017
  • Non-insulin Segment: Revenue Forecast, Malaysia, 2009-2017
  • Type 2 Diabetes Therapeutics Market: Pricing Analysis, Malaysia, 2012
  • Type 2 Diabetes Therapeutics Market: Prevalence and Treated Patient Forecast, Malaysia, 2009-2017
  • Type 2 Diabetes Therapeutics Market: Diabetes Outlook, Indonesia, 2012 and 2030
  • Insulin Segment: Revenue Forecast, Indonesia, 2009-2017
  • Non-insulin Segment: Revenue Forecast, Indonesia, 2009-2017
  • Type 2 Diabetes Therapeutics Market: Prevalence and Treated Patient Forecast, Indonesia, 2009-2017
  • Type 2 Diabetes Therapeutics Market: Diabetes Outlook, Vietnam, 2012 and 2030
  • Insulin Segment: Revenue Forecast, Vietnam, 2009-2017
  • Non-insulin Segment: Revenue Forecast, Vietnam, 2009-2017
  • Type 2 Diabetes Therapeutics Market: Pricing Analysis, Vietnam, 2012
  • Type 2 Diabetes Market: Prevalence and Treated Patient Forecast, Vietnam, 2009-2017
  • Insulin Segment: Revenue Forecast, India, 2009-2017
  • Non-insulin Segment: Revenue Forecast, India, 2009-2017
  • Type 2 Diabetes Therapeutics Market: Pricing Analysis, India, 2012
  • Type 2 Diabetes Therapeutics Market: Prevalence and Treated Patient Forecast, India, 2009-2017
  • Decision Support Database: Prevalence of Type-2 Diabetes, Global, 2008-2018
  • Decision Support Database: Percent of Prevalence of Type-2 Diabetes, Global, 2008-2018
Back to Top